University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 42 Trials 
79 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bernard, Stephen A
STEPCARE, NCT05564754 / ACTRN12623001057673: Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation

Recruiting
N/A
3500
Europe, RoW
Feedback-controlled temperature device, High MAP, Deep sedation, Fever control without a device, Low MAP, Minimal sedation
Region Skane, Lund University, Lund, Sweden, Copenhagen Trial Unit, Center for Clinical Intervention Research, The George Institute for Global Health, Australia, HUS Helsinki University Hospitals, Helsinki, Finland, Medical Research Institute of New Zealand Rangahautia Te Ora, Wellington, New Zealand
Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain
12/25
06/26
O'Neil, Bert H
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
NCT05249101: A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

Recruiting
1/2
70
US
Ivaltinostat, Capecitabine, Xeloda
CG Pharmaceuticals, Inc
Metastatic Pancreatic Adenocarcinoma
02/26
06/26
NCT04657068: A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Recruiting
1/2
547
Europe, US
ART0380, Gemcitabine, Gemzar, Irinotecan, Camptosar, Camptothecin-11
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
06/25
GV20-0251-100, NCT05669430: A Study of GV20-0251 Monotherapy and GV20-0251 in Combination with Pembrolizumab in Participants with Solid Tumor Malignancies

Recruiting
1/2
365
US
GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], MK-3475
GV20 Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, PMMR/MSS Adenocarcinoma of the Colon or Rectum, Cutaneous Melanoma, Non-Small Cell Lung Cancer
12/26
09/27
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruiting
1
500
Europe, Japan, US, RoW
LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Eli Lilly and Company
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
06/20
12/27
NCT04965818: Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Terminated
1
38
US
Futibatinib and Binimetinib
Taiho Oncology, Inc.
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation
06/23
09/23
SGNB7H4V-001, NCT05194072: A Study of SGN-B7H4V in Advanced Solid Tumors

Active, not recruiting
1
572
Europe, Canada, US
SGN-B7H4V, Pembrolizumab, Keytruda
Seagen Inc.
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
11/27
11/27
Smith, Phillip B
HONEY-POT, NCT06275698: HONEY for the Treatment of POst-Tonsillectomy Pain

Recruiting
N/A
100
Europe
Manuka honey MGO 1000, Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring
East and North Hertfordshire NHS Trust, Manuka Doctor UK Ltd, National Institute for Health Research, United Kingdom
Post Surgical Pain, Analgesia
09/25
09/25
SEISMIC-R, NCT05917574: A Study to Evaluate the Introduction of New Staffing Models in Intensive Care: a Realist Evaluation

Recruiting
N/A
80
Europe
n/a (non-interventional)
University of Hertfordshire, University of Southampton, Imperial College Healthcare NHS Trust, Intensive Care National Audit & Research Centre, University of Exeter, University of Plymouth, London South Bank University
Critical Illness, Staff Attitude, Organisation, Intensive Care
01/25
04/25
NCT05538351: A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury

Recruiting
N/A
120
Europe
Body Composition Monitor (BCM), Bioimpedance
University of Hertfordshire, East and North Hertfordshire NHS Trust
Acute Kidney Injury
08/25
08/25
Sanoff, Hanna
SOLARIS, NCT04094688: Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer

Active, not recruiting
3
455
US
Bevacizumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan, Cholecalciferol, Vitamin D3, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Colorectal Adenocarcinoma
01/26
07/26
COMMIT, NCT02997228: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the Study

Recruiting
3
120
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, Elplat, JM 83, JM-83, JM83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, RP54780, SR 96669, SR-96669, SR96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI), NRG Oncology
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
06/27
06/27
CABINET, NCT03375320: Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Hourglass Feb 2020 - Dec 2020 : Data from CABINET trial for advanced NET
Active, not recruiting
3
298
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Carcinoid Tumor, Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
08/23
11/25
COBRA, NCT04068103: Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Active, not recruiting
2/3
1408
Canada, US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, citrovorum factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Patient Observation, Active Surveillance, deferred therapy, expectant management, observation, Watchful Waiting
NRG Oncology, National Cancer Institute (NCI)
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
06/23
04/27
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
JANUS, NCT05610163: Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation

Recruiting
2
312
US
Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC V8, Stage III Rectal Cancer AJCC V8
09/25
09/32
LCCC1717, NCT03446157: Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Active, not recruiting
2
24
US
Cetuximab, Erbitux, Palbociclib, Ibrance
UNC Lineberger Comprehensive Cancer Center, Amgen, Pfizer
Cancer of the Colon, Colon Cancer, Colon Neoplasms, Colonic Cancer, Neoplasms, Colonic
05/23
01/26
NCT03977233: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Recruiting
2
45
US
Oxaliplatin, Eloxatin, Leucovorin, folinic acid, Irinotecan Hydrochloride, Camptosar, 5-FU, Adrucil
UNC Lineberger Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
07/27
01/30
RGX-202-001, NCT03597581: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Recruiting
1
108
US
ompenaclid, RGX-202-01, FOLFIRI, Bevacizumab, FOLFOX regimen
Inspirna, Inc.
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
12/24
12/24
NCT03454035: Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Recruiting
1
45
US
Ulixertinib, BVD-523, Palbociclib, Ibrance
UNC Lineberger Comprehensive Cancer Center, BioMed Valley Discoveries, Inc, Pfizer
Tumor, Solid, Pancreatic Cancer, Melanoma
08/25
11/26
McRee, Autumn
NCT03783936: Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Completed
2
18
US
Oxaliplatin, Leucovorin, 5 fluorouracil, Trastuzumab, Avelumab
Ashwin Somasundaram, EMD Serono, University of North Carolina, Chapel Hill
Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis, HER-2 Gene Amplification
09/20
08/22
NCT03442569: PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Active, not recruiting
2
56
US
Panitumumab, Vectibix, Nivolumab, Opdivo, Ipilimumab, Yervoy
UNC Lineberger Comprehensive Cancer Center, Amgen, Bristol-Myers Squibb
Colon Cancer
09/20
12/24
NCT04386057: LY3214996 +/- HCQ in Pancreatic Cancer

Completed
2
52
US
Hydroxychloroquine Sulfate, Plaquenil®), HCQ, LY3214996
Kimberly Perez, MD, Eli Lilly and Company
Pancreatic Cancer, Advanced Cancer
08/23
02/24
NCT00819208: Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Active, not recruiting
N/A
889
Europe, Canada, US, RoW
exercise intervention, counseling intervention, educational intervention, laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, fatigue assessment and management, quality-of-life assessment, Educational Intervention, Fitness testing
Canadian Cancer Trials Group, Survivorship Research Group, Queen's University, Belfast
Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders, Excercise
12/29
12/30
Rossi, Emma
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Bae-Jump, Victoria
NCT02065687: Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

Active, not recruiting
2/3
469
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Laboratory Biomarker Analysis, Metformin Hydrochloride, APO-Metformin, Cidophage, Dimefor, Glifage, Glucoformin, Glucophage, Glucophage ER, Metformin HCl, Riomet, Siofor, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Gynecologic Oncology Group, National Cancer Institute (NCI)
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
04/19
09/23
NCT02035787: Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients

Completed
2
20
US
Metformin, glucophage
UNC Lineberger Comprehensive Cancer Center, Golfers Against Cancer
Complex Atypical Hyperplasia, Endometrial Cancer
10/23
04/24
NCT05483023: 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy

Recruiting
2
8
US
18F-fluorofuranylnorprogesterone PET / MRI
UNC Lineberger Comprehensive Cancer Center, Radiological Society of North America
Complex Atypical Hyperplasia, Endometrial Cancer
06/25
12/26
NCT03694834: Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer

Terminated
1
3
US
Pembrolizumab, Keytruda, Hysterectomy
UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Endometrial Cancer, Uterine Cancer
10/23
10/23
NCT05542407: ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Recruiting
1
58
US
Atezolizumab, ONC201
UNC Lineberger Comprehensive Cancer Center, Genentech, Inc., Oncoceutics, Inc., National Cancer Institute (NCI)
Endometrial Cancer, Metastasis
02/26
07/26
SISTER, NCT04930159: Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence

Recruiting
N/A
252
US
Facilitated group support, 1:1 Peer Support
University of Washington, Patient-Centered Outcomes Research Institute
Endometrial Cancer
06/25
03/26
NCT04025229: High Intensity Interval Training in Endometrial Cancer

Active, not recruiting
N/A
32
US
HIIT exercise
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Endometrial Cancer
09/25
09/25
Kim, Hong Kyun
NCT01937806: Phase 3 and Extensional Study of Besifovir

Active, not recruiting
3
197
RoW
besifovir 150mg, tenofovir 300mg
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
02/16
01/23
NCT05733624: Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

Completed
2
116
RoW
SCAI-001 0.01% eyedrop, Cyclosporine 0.01%, SCAI-001 0.02% eyedrop, Cyclosporine 0.02%, Restasis 0.05% eyedrop, Cyclosporine 0.05%
SCAI Therapeutics
Dry Eye Syndromes
08/23
02/24
NCT03977233: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Recruiting
2
45
US
Oxaliplatin, Eloxatin, Leucovorin, folinic acid, Irinotecan Hydrochloride, Camptosar, 5-FU, Adrucil
UNC Lineberger Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
07/27
01/30
NCT03705546: The Impact of Physical Activity on the Postoperative Symptoms, Complications, and Quality of Life Among Lung Cancer

Active, not recruiting
N/A
1050
RoW
Samsung Medical Center
Lung Neoplasms
12/20
03/26
NCT05262452: Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer

Recruiting
N/A
60
RoW
ALPIUS 900, an ultrasound-guided high intensity focused ultrasound system, FOLFIRINOX regimen
Seoul National University Hospital, Focused Ultrasound Foundation, Synex Consulting Ltd
Pancreatic Cancer Non-resectable, Chemotherapy Effect, Ultrasound Therapy
03/23
12/24
ASSURE, NCT03306901: Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma

Active, not recruiting
N/A
240
RoW
Esophagectomy, 5-fluorouracil, 5-FU, Cisplatin, Radiation therapy
Samsung Medical Center, Ministry of Health & Welfare, Korea
Esophageal Cancer
12/25
12/33
OREX-IA, NCT03066297: Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung Cancer

Active, not recruiting
N/A
1018
RoW
Extent of pulmonary resection
Samsung Medical Center
Stage IA Non-small Cell Lung Cancer
02/27
02/27
Lee, Michael Kang-Yin
IIH EVOLVE, NCT05347147 / 2021-006664-24: A Trial to Determine the Efficacy and Safety of Presendin in IIH

Terminated
3
14
Europe, US, RoW
Presendin, Placebo
Invex Therapeutics Ltd., Premier Research Group plc, University Hospitals Birmingham Neuro Ophthalmology Reading Centre, Birmingham, UK, Iowa Visual Field Reading Centre, Iowa, USA
Idiopathic Intracranial Hypertension
09/23
10/23
PICASSO, NCT05611242: Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial

Recruiting
3
404
US
MT+CAS with IV-AP, Thrombectomy, MT+CAS with PO-AP, MT+CAT with PO-AP
Mercy Health Ohio
Acute Ischemic Stroke
03/26
05/27
NCT05733611: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Active, not recruiting
2
4
NA
RP2, RP3, atezolizumab, bevacizumab
Replimune Inc., Roche Pharma AG
Refractory Metastatic Colorectal Cancer, pMMR, MSS
01/27
03/27
NCT03977233: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Recruiting
2
45
US
Oxaliplatin, Eloxatin, Leucovorin, folinic acid, Irinotecan Hydrochloride, Camptosar, 5-FU, Adrucil
UNC Lineberger Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
07/27
01/30
NCT05176665: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Recruiting
1/2
152
US, RoW
EMB-01, FIT-013a
Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc
Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor
12/25
12/25
PERIO-03, NCT05607953: Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Recruiting
1
60
US
SD-101, anti-PD-1
TriSalus Life Sciences, Inc.
Locally Advanced Pancreatic Adenocarcinoma
10/24
10/26
BIOSOLVE-IV, NCT02817802: BIOTRONIKS - Safety and Performance in de NOvo Lesion of NatiVE Coronary Arteries With Magmaris- Registry:

Active, not recruiting
N/A
2066
Europe, RoW
Magmaris
Biotronik AG
Coronary Artery Disease
07/20
10/25
VANGAS, NCT06211725: The -Trial. The Value of Neurofilament Light Chain and Glial Fibrillary Acid Protein in the Blood of Patients With Asymptomatic Carotid Artery Stenosis

Recruiting
N/A
200
Europe
Heinrich-Heine University, Duesseldorf
Carotid Artery Stenosis, Carotid Artery Stenosis Asymptomatic, Carotid Artery Diseases, Carotid Artery Plaque
01/25
01/25
NCT05189171: MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer

Completed
N/A
46
US
MicroOrganoSphere (MOS) drug screen
Xilis, Inc.
Colorectal Neoplasms
11/23
03/24
Baron, Todd H
NCT03977233: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Recruiting
2
45
US
Oxaliplatin, Eloxatin, Leucovorin, folinic acid, Irinotecan Hydrochloride, Camptosar, 5-FU, Adrucil
UNC Lineberger Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
07/27
01/30
NCT03259763: EUS-GE vs ES for Palliation of Gastric Outlet Obstruction

Recruiting
N/A
112
Europe, Canada, US, RoW
Lumen-apposing metal stent, Self-expandable metal stent
Johns Hopkins University, Boston Scientific Corporation
Gastric Outlet Obstruction
10/25
08/26
VIABILITY, NCT05820009: GORE® VIABIL® Biliary Endoprosthesis in the Treatment of Benign Biliary Strictures Secondary to Chronic Pancreatitis

Suspended
N/A
133
US
GORE® VIABIL® Biliary Endoprosthesis, GORE® VIABIL® Short Wire Biliary Endoprosthesis
W.L.Gore & Associates
Pancreatitis, Chronic, Stricture; Bile Duct
08/26
08/28
Carlson, Cheryl
NCT03977233: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Recruiting
2
45
US
Oxaliplatin, Eloxatin, Leucovorin, folinic acid, Irinotecan Hydrochloride, Camptosar, 5-FU, Adrucil
UNC Lineberger Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
07/27
01/30
Triglianos, Tammy
NCT03977233: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Recruiting
2
45
US
Oxaliplatin, Eloxatin, Leucovorin, folinic acid, Irinotecan Hydrochloride, Camptosar, 5-FU, Adrucil
UNC Lineberger Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
07/27
01/30
Yeh, Jen Jen
NCT03977233: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Recruiting
2
45
US
Oxaliplatin, Eloxatin, Leucovorin, folinic acid, Irinotecan Hydrochloride, Camptosar, 5-FU, Adrucil
UNC Lineberger Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
07/27
01/30
PROCLAIM, NCT06252545: Promoting CT Engagement for Pancreatic Cancer With App

Recruiting
N/A
26
US
semistructured interviews, feedback
UNC Lineberger Comprehensive Cancer Center, Lustgarten Foundation
Pancreas Cancer
02/27
02/27
EA2185, NCT04239573: Comparing Two Methods to Follow Patients With Pancreatic Cysts

Recruiting
N/A
4606
Canada, US, RoW
Computed Tomography, CAT, CAT scan, Computerized Axial Tomography, computerized tomography, CT, CT scan, tomography, Endoscopic Ultrasound, endosonography, EUS, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, nuclear magnetic resonance imaging, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Pancreatic Carcinoma
07/33
07/33
Clark, Leslie
NCT04576104: Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer

Recruiting
2
50
US
Biopsy, BIOPSY_TYPE, Bx, Extended Release Metformin Hydrochloride, ER Metformin Hydrochloride, Extended-release Metformin Hydrochloride, Glucophage XR, Glumetza, Metformin Hydrochloride Extended Release, Megestrol Acetate, 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate, 17.alpha.-Acetoxy-6-methylpregna-4,6-diene-3,20-dione, 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone, 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone, BDH 1298, BDH-1298, Maygace, Megace, Megestat, Megestil, Niagestin, Ovaban, Pallace, SC 10363, SC-10363, Questionnaire Administration
National Cancer Institute (NCI)
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma
11/25
05/26
Maduekwe, Ugwuji
NCT03977233: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Recruiting
2
45
US
Oxaliplatin, Eloxatin, Leucovorin, folinic acid, Irinotecan Hydrochloride, Camptosar, 5-FU, Adrucil
UNC Lineberger Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
07/27
01/30
PROCLAIM, NCT06252545: Promoting CT Engagement for Pancreatic Cancer With App

Recruiting
N/A
26
US
semistructured interviews, feedback
UNC Lineberger Comprehensive Cancer Center, Lustgarten Foundation
Pancreas Cancer
02/27
02/27
Somasundaram, Ashwin
A022102, NCT05677490: MFOLFIRINOX Versus MFOLFOX with or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Recruiting
3
382
US
Fluorouracil, 2,4-Dioxo-5-fluoropyrimidine, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluoro-2,4(1H,3H)-pyrimidinedione,, Leucovorin Calcium, 1492-18-8, 5-Formyl Tetrahydrofolate, Calcium (6S)-Folinate, Calcium Folinate, Oxaliplatin, 1-OHP, Dacotin, Dacplat, ELOXATIN, Irinotecan, Nivolumab, MDX-1106, Opdivo, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, Computed Axial Tomography, CT Scan, Biospecimen Collection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC V8, Clinical Stage III Gastric Cancer AJCC V8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC V8, Clinical Stage IV Esophageal Adenocarcinoma AJCC V8, Clinical Stage IV Gastric Cancer AJCC V8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
11/28
11/28
NCT03783936: Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Completed
2
18
US
Oxaliplatin, Leucovorin, 5 fluorouracil, Trastuzumab, Avelumab
Ashwin Somasundaram, EMD Serono, University of North Carolina, Chapel Hill
Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis, HER-2 Gene Amplification
09/20
08/22
NCT05733611: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Active, not recruiting
2
4
NA
RP2, RP3, atezolizumab, bevacizumab
Replimune Inc., Roche Pharma AG
Refractory Metastatic Colorectal Cancer, pMMR, MSS
01/27
03/27
NCT03977233: Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Recruiting
2
45
US
Oxaliplatin, Eloxatin, Leucovorin, folinic acid, Irinotecan Hydrochloride, Camptosar, 5-FU, Adrucil
UNC Lineberger Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
07/27
01/30
PANGEA, NCT06483555: Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

Not yet recruiting
1/2
104
US
Gemcitabine, Gemcitabine hydrochloride, FF 10832, LY188011, C9H11F2N3O4 - HCl, Nab paclitaxel, Abraxane, Erlotinib, Tarceva, NALIRIFOX, A combination of liposomal irinotecan,5 fluorouracil /leucovorin and oxaliplatin., Folfirinox, It is a combination of leucovorin calcium (folinic acid), fluorouracil, irinotecan hydrochloride, and oxaliplatin
UNC Lineberger Comprehensive Cancer Center
Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm
08/27
08/27
GI15-225, NCT03099564: Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

Active, not recruiting
1
30
US
Pembrolizumab, Keytruda®, Y90 radioembolization
Ashwin Somasundaram, Merck Sharp & Dohme LLC, Hoosier Cancer Research Network
Hepatocellular Carcinoma
05/21
06/23
NCT05411094: Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Recruiting
1
18
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Radiologic Examination, Radiologic Evaluation, Radiologic Exam
National Cancer Institute (NCI)
Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
06/25
06/25
NCT06158139: Autologous CAR-T Cells Targeting B7-H3 in PDAC

Recruiting
1
27
US
iC9-CAR.B7-H3 T cell infusion, Cellular Therapy
UNC Lineberger Comprehensive Cancer Center
Pancreas Cancer, Relapse, Resistant Cancer
06/26
06/28
NCT05685602: CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Recruiting
1
36
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Emavusertib, AU 4948, AU-4948, CA 4948, CA-4948, CA4948, Interleukin-1 Receptor-associated Kinase 4 Inhibitor CA-4948, IRAK4 Inhibitor CA-4948, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nab-paclitaxel, ABI 007, ABI-007, ABI007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Naveruclif, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
03/25
03/25
Babinec, Caroline
NCT05634785: CD30 CAR for CD30+ NSGCT

Recruiting
2
18
US
ATLCAR.CD30 Cells, CAR.CD30 T cells, Cyclophosphamid, Cytoxan, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center, University Cancer Research Fund at Lineberger Comprehensive Cancer Center
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor
12/26
12/26
NCT04083495: CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Recruiting
2
20
US
ATLCAR.CD30 T cells, Bendamustine, Bendeka, Fludarabine, Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Peripheral T Cell Lymphoma
02/28
08/38
NCT02690545: Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Recruiting
1/2
40
US
ATLCAR.CD30 cells, CAR.CD30 T cells
UNC Lineberger Comprehensive Cancer Center
Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
09/27
08/38
NCT04134325: Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting
1
10
US
Nivolumab, Opdivo, Pembrolizumab, Keytruda
UNC Lineberger Comprehensive Cancer Center, American Society of Clinical Oncology
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
04/25
07/37
NCT03721068: Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Recruiting
1
18
US
iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine
UNC Lineberger Comprehensive Cancer Center, United States Department of Defense, Bellicum Pharmaceuticals, University Cancer Research Fund at Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Neuroblastoma, Osteosarcoma
05/25
06/39
NCT06158139: Autologous CAR-T Cells Targeting B7-H3 in PDAC

Recruiting
1
27
US
iC9-CAR.B7-H3 T cell infusion, Cellular Therapy
UNC Lineberger Comprehensive Cancer Center
Pancreas Cancer, Relapse, Resistant Cancer
06/26
06/28
NCT06305299: Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Recruiting
1
27
US
iC9-CAR.B7-H3 T cells, iC9-CAR.B7-H3 T, Cyclophosphamide, Cycloblastin, Endoxan, Neosar, Procytox, Revimmune, Fludarabine, Fludara, Fludarabine Phosphate
UNC Lineberger Comprehensive Cancer Center
Ovary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent
03/26
03/26
NCT05366179: Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

Recruiting
1
36
US
CAR.B7-H3T cells infusion
UNC Lineberger Comprehensive Cancer Center
Glioblastoma Multiforme
05/30
05/30
NCT05620342: Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Recruiting
1
24
US
iC9.GD2.CAR.IL-15 T Infusion
UNC Lineberger Comprehensive Cancer Center, Bellicum Pharmaceuticals, United States Department of Defense
Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
02/25
02/27
LCCC 1606-ATL, NCT03602157: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Recruiting
1
59
US
ATLCAR.CD30.CCR4 cells, ALTCAR.CD30 cells, Bendamustine, Fludarabine
UNC Lineberger Comprehensive Cancer Center, University Cancer Research Fund at Lineberger Comprehensive Cancer Center, Stand Up To Cancer, National Cancer Institute (NCI)
Lymphoma, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Cutaneous Lymphoma, Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis, Cutaneous T Cell Lymphoma, Gray Zone Lymphoma
09/26
09/41
Asher, Claire
No trials found

Download Options